Pennant Group stock
PNTGNASDAQThe Pennant Group, Inc., HealthcareISIN US70805E1091
53Score 53 out of 100, Neutral
Price and trend
54 / 100
Price history
+42% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 0.2% above it.
Since December 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 33).
The price is 18% below its 52-week high. Largest decline in 7 years: 86% (January 2021 to October 2022).
Chart figures for advanced users
- SMA 50$40.09
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$35.85
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)33
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$24.89
- The lowest closing price of the last twelve months.
- Resistance$44.04
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- The Pennant Group, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $1.26B, is number 42 of 57 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $947.71M (up 36.3% year on year) and earnings of $29.58M (up 31.1%).
- For fiscal 2026, analysts expect on average revenue of $1.18B (up 24.9%) and adjusted earnings per share of $1.40 (up 18.8%).
Show more
- MEQIRI Score 53 out of 100 (Neutral): rank 354 of 702 in Healthcare, median 53.
- The P/E is 36.4 (Medical (Care Facilities) median 19.6, own median of recent years 36.8).
- Our model puts fair value at $31.02, with the price 16% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 19.4% a year since 2020, Medical (Care Facilities) median 9.2%.Growth 66
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 68
Weaknesses
- DilutionShare count up 23% since 2020.Capital allocation 32
The score is held back by valuation and capital allocation.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 54 to 53.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $22.16 and expensive above $51.70 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $42.68 (cash-flow model) and $19.37 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $27.21, at 7.8% it would be $36.77.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 38.7% on the twelve months before. Revenue has grown strongly since 2016, at around 18% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 13%, operating 5%, net 3%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 4 Nov 2026EPS reported $0.35 (expected $0.36)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.40+0.4%
- Revenue
- $1.18B0.0%
- Earnings per share
- $1.58−0.1%
- Revenue
- $1.28B+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +10.4%Guidance not adjusted, with a pointer to the upper end of the range; a guidance update is expected in the second quarter.
“With only one quarter behind us and substantial additional transition work on the near horizon, we are not adjusting guidance at this time, but would point you to the upper end of our guidance range.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $690,085 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Pennant Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 53
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Aevis VictoriaAEVS.SW $1.44B34
- AMN Healthcare ServicesAMN $1.44B65
- ClarianeCLARI.PA $1.37B39
- Innovage HoldingINNV $1.28B58
- Nutex HealthNUTX $1.18B73
- RHÖN-KLINIKUMRHK.DE $1.08B58
- Ramsay Générale de SantéGDS.PA $1.05B39
- Clínica BavieraCBAV.MC $938.01M80
ETFs that hold Pennant Group
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.10% | 0.40% | €813.42M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.06% | 0.43% | €2.5B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.05% | 0.30% | €185.82M |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.22B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.04% | 0.10% | €395.74M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €964.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 28 Feb 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.